Porfimer sodium
As of the edition of 20 October 2026, Porfimer sodium is a small molecule: marketed, first approved in 1995 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Photofrin
- First approved
- 27 December 1995 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- AXCAN SCANDIPHARM; 2 holders in all
- Withdrawn from market
- 20 April 2012 (in some regions)
- Registered trials
- 26, 7 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Mouth and teeth; Hormones; Ear, nose and throat
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 2 |
| Phase 1 | 8 | 5 | 0 | 2 |
| Phase 2 | 10 | 7 | 1 | 2 |
| Phase 3 | 4 | 1 | 0 | 1 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pinnacle Biologics | Acquired holder | 2019 to now |
| Qlt | Originator | 1995 to 2019 |